SVRA Stock Forecast: Savara, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$4.25
−18.43% on the day

The 9 Wall Street analysts covering Savara, Inc. hold a median 12-month price target of $11 — +147.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 28 of 100 as at 21 Nov 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$939.9M
Ticker Nerd rank
28/ 100
Median analyst target
$11
Analysts covering
9
Revenue$0.0
Operating income−$41.0M
Net income−$40.2M
Free cash flow−$30.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−8.4%
1M
−10.7%
YTD
−29.5%
1Y
−9.0%
From 52W high
−38.8%
From 52W low
+0.7%
$4.22
$6.94
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Savara, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
28/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
75
Momentum
65
Value
61
Accruals
53
Revisions
28
Growth
28
Issuance
27
Quality
23

Volatility (75): The share price has been relatively steady.

Quality (23): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

SVRA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SVRA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$4.00$6.00$8.00$10.00$12.00$14.00$16.00Jan 26Apr 26Jul 26Oct 26SVRAHigh $16Median $11Low $9

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
9
Buy
0
Hold
0
Sell
$9
Low
$11
Median
$16
High

The green dot is the last close — the median target sits +147.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
12 Nov 2026HC Wainwright & Co.AssumesBuy$10
7 Oct 2026JP MorganInitiatesOverweight$12
23 Dec 2025HC Wainwright & Co.MaintainsBuy$8.00 → $10
18 Dec 2025Wells FargoMaintainsOverweight$7.00 → $9.00
14 Nov 2025OppenheimerMaintainsOutperform—
13 Nov 2025CitizensMaintainsMarket Outperform—
23 Oct 2025JMP SecuritiesMaintainsMarket Outperform—
9 Sept 2025GuggenheimMaintainsBuy—
8 Sept 2025OppenheimerMaintainsOutperform—
3 Sept 2025HC Wainwright & Co.MaintainsBuy—
15 Aug 2025HC Wainwright & Co.UpgradeBuy—
15 Aug 2025OppenheimerMaintainsOutperform—
1 June 2025OppenheimerMaintainsOutperform—
29 May 2025HC Wainwright & Co.DowngradeNeutral—
28 May 2025Evercore ISI GroupMaintainsIn-Line—
28 May 2025GuggenheimMaintainsBuy—
28 May 2025Wells FargoMaintainsOverweight—
31 Mar 2025Evercore ISI GroupMaintainsHold—
28 Mar 2025HC Wainwright & Co.ReiteratesBuy—
20 Dec 2024Wells FargoInitiatesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for SVRA.

Market Radar

This page is one stock. Monday covers all of them.

SVRA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

SVRA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Savara, Inc. returned −9.0% against +6.9% for the S&P 500, dividends included.

SVRA vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130140150Jan 26Apr 26Jul 26Oct 26SVRAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SVRA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
4
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
10.0×

Cheaper than 7% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−151.0%

Higher than 9% of US stocks

Return on assets
−65.7%

Higher than 5% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Savara, Inc. has a market value of $939.9M and an enterprise value of $1.0B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$139.3M.

  • Free cash flow in the twelve months to 30 June 2026: −$110.7M.

  • Savara, Inc. spent $5.1M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 205.4M.

  • Savara, Inc. employs 70 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

SVRA and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SVRASavara, Inc.$939.9M28
MLTXMoonLake Immunotherapeutics$942.1M14
SPTXSeaport Therapeutics, Inc.$957.2M13
OMEROmeros Corp.$983.7M81
ANROAlto Neuroscience, Inc.$986.1M57
AKTSAktis Oncology, Inc.$892.7M2
CTYCity Therapeutics, Inc.$999.3M1

Take a look at SVRA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Savara, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about SVRA

What is the SVRA stock price forecast for 2026-2027?

The 9 Wall Street analysts covering Savara, Inc. have a median 12-month price target of $11, with estimates ranging from $9 to $16. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SVRA stock a buy right now?

Of the 9 analysts covering Savara, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Savara, Inc. 28 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SVRA?

As at 21 Nov 2026, Savara, Inc. ranks 28 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (75 of 100).

Will SVRA stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +147.1% from the last close, and Ticker Nerd's factor model ranks Savara, Inc. 28 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SVRA stock forecast for 2030?

No analyst covering Savara, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SVRA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $16 over the next 12 months.

How has SVRA stock performed over the past year?

Savara, Inc. returned -9.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Savara, Inc. do?

Savara Inc. is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. The company’s work centers on developing inhaled therapies designed to address serious lung disorders with limited treatment options, with a particular emphasis on autoimmune pulmonary alveolar proteinosis.

Company

About Savara, Inc.

Savara Inc. is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. The company’s work centers on developing inhaled therapies designed to address serious lung disorders with limited treatment options, with a particular emphasis on autoimmune pulmonary alveolar proteinosis. Its lead product candidate, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor being advanced through late-stage clinical development. Savara’s current business is concentrated on research, clinical development, and regulatory progress in orphan and specialty respiratory medicine, rather than on a broad commercial product portfolio. The company serves a niche market within biotechnology and pharmaceuticals, where expertise in pulmonary medicine and rare disease development is central to its role.

CEO Mr. Matthew Pauls J.D., M.B.A. · 70 employees · United States · https://www.savarapharma.com